price
PT
AMEX · PTN
Palatin Technologies, Inc.
Healthcare · Biotechnology
$10.94
Down-$2.42 (-18.11%)
Updated Sep 16, 2026, 10:53 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 641.56M
- P/E ratio
- -4.99
- Dividend yield
- 0.00%
- 52-week range
- $7.21 – $23.78
- Volume
- 147.64K
- Avg. volume
- 1.78M
Price performance
PTN price history
1M range · 0 trading sessions · Daily adjusted prices
PTN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest PTN news
The latest Smart Investors Daily articles mentioning PTN.
Stock researchCompany · Overview
PTN research
Overview
Company profile and research snapshot.
Company profile
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $50.00
- Implied upside
- —
- Analysts
- 5
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 12, 2025 | Laidlaw & Co. | Buy | — |
| Feb 13, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 7, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 29, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 28, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.